Exhibit 10.1


 


November 30, 2022


 


Aziyo Biologics, Inc.


12510 Prosperity Drive, Suite 370


Silver Spring, MD 20904


Email: jhamet@aziyo.com


 


RE:          Amendment
Letter


 


Ladies and Gentlemen:


 


Reference is made to that certain
Credit Agreement, dated as of August 10, 2022, by and among Aziyo Biologics, Inc., a Delaware corporation (the “Borrower”),
each of the undersigned financial institutions (individually each a “Lender” and collectively the “Lenders”)
and SWK Funding LLC, a Delaware limited liability company, in its capacity as administrative agent for the other Lenders (in such capacity,
 “Agent”) (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”).
All capitalized terms used in this amendment letter (this “Amendment Letter”) and not otherwise defined herein, shall
have the respective meanings given such terms in the Credit Agreement.


 


Notwithstanding the fact that
the Subsequent Term Loan Conditions have not otherwise been satisfied, at the request of Borrower, Agent and Lenders hereby agree to fund
the Subsequent Term Loan in the amount of $4,000,000, within five (5) Business Days of Agent’s receipt of a written request
from Borrower, so long as (i) Agent receives such written request on or prior to December 16, 2022, (ii) no Material Adverse
Effect, Default or Event of Default has occurred and is continuing, or would be caused thereby, as of the date of such funding and (iii) Borrower
shall have issued additional Equity Interests on or prior to the date of such funding resulting in net proceeds to Borrower of not less
than $10,000,000. For the avoidance of doubt, full satisfaction of the Subsequent Term Loan Conditions shall be required for purposes
of Sections 2.6.2 and 2.9.1(b)(iv)(B).


 


Borrower shall promptly make
its Chief Scientific Officer available for one or more due diligence telephonic meetings as requested by Agent to discuss the status of
the CanGaroo RM Product’s FDA approval process and the latest correspondence with the FDA in connection therewith.


 


Except for the amendments
expressly set forth above, all of the terms, provisions and conditions of the Credit Agreement and the other Loan Documents shall remain
and continue in full force and effect. This Amendment Letter shall not apply to any other past, present or future deviations from the
Credit Agreement or any other Loan Document. Except as expressly provided herein, Agent or any Lender’s failure to exercise any
right, privilege or remedy as a result of the matters set forth above shall not directly or indirectly in any way whatsoever either: (a) impair,
prejudice or otherwise adversely affect Agent or any Lender’s right at any time to exercise any right, privilege, or remedy in connection
with the Credit Agreement, the other Loan Documents, any other agreement, or any other contract or instrument in connection therewith,
or (b) amend or alter any provision of the Credit Agreement, the other Loan Documents, any other agreement, or any other contract
or instrument in connection therewith, or (c) constitute any course of dealing or other basis for altering any obligations of Borrower
or any right, privilege, or remedy of Agent or any Lender under the Credit Agreement, the other Loan Documents, any other agreement, or
any other contract or instrument in connection therewith. Agent and each Lender hereby reserve all rights granted under the Credit Agreement,
the other Loan Documents, this Amendment Letter and any other contract or instrument between Borrower, Agent or any Lender in connection
therewith. Except as expressly stated herein, Agent and each Lender reserve all of their respective rights, privileges and remedies under
the Credit Agreement, the other Loan Documents, each other agreement and any other contracts or instruments executed by Borrower for the
benefit of Agent or such Lender in connection therewith.


 






    


     


    

 


Borrower hereby represents and
warrants that (i) each of the representations and warranties contained in the Credit Agreement, is true, correct and complete in
all material respects as of the date hereof; provided, however, that those representations and warranties expressly referring
to a specific date shall be true, correct and complete in all material respects as of such date and (ii) no Default or Event of Default
exists.


 


This Amendment Letter shall
not become effective until Agent has received an executed and delivered signature page to this Amendment Letter by the Borrower.


 


Borrower represents that it
has discussed this Amendment Letter with its counsel.


 


THE
TERMS AND PROVISIONS OF SECTION 10.17 (GOVERNING LAW) AND 10.18 (FORUM SELECTION; CONSENT TO JURISDICTION) OF THE CREDIT AGREEMENT
ARE HEREBY INCORPORATED HEREIN BY REFERENCE, and SHALL APPLY TO THIS AMENDMENT LETTER MUTATIS MUTANDIS AS IF FULLY SET FORTH HEREIN.


 


This Amendment Letter may be
executed in multiple counterparts, each of which shall constitute an original hereof, and all of which taken together shall constitute
one and the same agreement. One or more counterparts of this Amendment Letter may be delivered by facsimile or electronic (including “PDF”)
transmission, with the intention that delivery by such means shall have the same effect as delivery of an original counterpart thereof.


 


[Remainder
of Page Intentionally Left Blank]


 






    -2-


     


    


 


IN
WITNESS HEREOF, as of the date above-written, the undersigned hereby agree to the terms and conditions set forth in this Amendment
Letter.


 


	 	Very truly yours,
	 	 
	 	AGENT AND LENDER:
	 	 
	 	SWK FUNDING LLC
	 	As Agent and a Lender
	 	 
	 	By: SWK Holdings Corporation its sole manager
	 	
	 	By: 	/s/ Joe D. Staggs
	 	Name: 	Joe D. Staggs
	 	Title:	 President




 


[Additional signature pages follow]


 






     


     


    

 


	ACCEPTED AND AGREED TO:	 
	 	 
	AZIYO BIOLOGICS, INC.	 
	 	 
	 	 
	By:	/s/
    Matt Ferguson	 
	Name: 	Matt Ferguson	 
	Title:	Chief Financial Officer